AbbVie Inc. (NYSE: ABBV) is rewarding its shareholders once again with a quarterly dividend of $1.64, payable on Friday, Feb.

The North Chicago drugmaker says it could pay Xilio Therapeutics more than $2.1 billion in a collaboration and ...

AbbVie Inc . (NYSE:ABBV), currently trading at $190.14, has demonstrated resilience and strategic foresight as it navigates the loss of exclusivity for its blockbuster drug Humira. The ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

AbbVie (NYSE:ABBV) will report Q4 2024 results ... meaning the upside to expectations comes from the existing and long-lived branded products and not because Humira is holding up better than ...

AbbVie has been named a Top Socially Responsible ... considerations like the environmental impact of the company's products and services, as well as the company's efficiency in terms of its ...

and despite setbacks on its way to market has become one of AbbVie's fastest-growing products with sales expected to reach around $2.2 billion this year, up from just over $1.7 billion in 2021.

AbbVie cautions that these forward-looking statements ... competition from other products, difficulties inherent in the research and development process, adverse litigation or government action ...

AbbVie's underlying business remains strong, and so does its dividend program. The company is a Dividend King with 52 ...

AbbVie CEO Robert Michael will soon add the role of board chairman to his résumé. Michael, who became CEO of the North Chicago-based pharmaceutical giant last summer, will assume duties as ...

Danaher, Recursion Pharmaceuticals, Moderna, Thermo Fisher Scientific, AbbVie, Vertex Pharmaceuticals, and Cognizant Technology Solutions are the seven Biotech stocks to watch today, according to ...

the immune-disease drug that was once Abbvie's top-selling product, as well as slowing sales of the company's aesthetic products such as Botox.